Biotech Stock News

FDA decisions, clinical trial results, and biotech catalyst coverage. Analysis for investors tracking binary events, pipeline risk, and drug approvals.

By Basis Report editorial deskReviewed by Basis Report methodology teamMethodology

IBRXAnalysis2d ago · May 18, 2026

ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears

ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG to target a decade-long bladder cancer shortage, while a pivotal FDA decision on its Anktiva immunotherapy looms in the same week. Against 167.6% revenue growth and negative $194 million in trailing free cash flow, the company is stacking catalysts as it burns toward commercial scale.

IBRXBrief4d ago · May 17, 2026

ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling

ImmunityBio is acquiring U.S. rights to Tokyo strain BCG while bracing for an imminent Anktiva FDA ruling, a dual catalyst that creates a binary risk event for shareholders.

ZETAAnalysis4d ago · May 17, 2026

Zeta Global Joins Snowflake AI Standard, Stock Rises

Zeta Global's entry into a Snowflake-led AI marketing data standard lifted the stock, adding to momentum from three consecutive EPS beats with accelerating magnitude. With shares at $17.19 against a $28.77 consensus target and 49.9% revenue growth on a $1.44 billion trailing base, the valuation gap between current price and analyst consensus is the story.

ACHRAnalysisMay 11 · May 11, 2026

UAE Opens Path for Archer eVTOL; BlackRock Stakes 6.9%

The UAE opened a streamlined regulatory path for Archer Aviation's Midnight eVTOL aircraft while BlackRock disclosed a 6.9% ownership stake, providing headline support for a pre-revenue company burning $376 million annually in free cash flow. The picture is complicated by uniform C-suite selling across five executives in March, a CFO transition, and an earnings report due Monday, May 12.

NVTSAnalysisMay 9 · May 9, 2026

Navitas Earnings: AI Tailwind Meets Insider Selling

Navitas Semiconductor reported 18% Q1 2026 sales growth attributed to AI data center demand while trading at roughly 106x trailing twelve-month revenue of $40 million. Insider net sales of $4.97 million with zero purchases, four officer-change filings in under 60 days, and a trailing revenue decline of 38.7% complicate the bullish read.

HIMSBriefMay 9 · May 9, 2026

Hims & Hers Health Faces a 15% Stock Swing on Its Weight-Loss Pivot

Hims & Hers Health heads into Q1 earnings with options traders pricing a ~15% move in either direction, making the print a binary test of whether the GLP-1 weight-loss pivot can hold up against FDA compounding restrictions on semaglutide.

BBBriefMay 7 · May 7, 2026

BlackBerry Stock Jumps 10% on QNX Rewrite: Design Wins Still Unconfirmed

BlackBerry surged 10% in a single session after announcing a ground-up QNX rewrite, but the stock's 29.9x forward P/E on $549mn TTM revenue prices in OEM and robotics contracts that have not been confirmed yet.

USARAnalysisMay 2 · May 2, 2026

USAR Seals $2.8B Brazil Deal as BlackRock Takes Stake

USA Rare Earth has agreed to acquire Brazil's Serra Verde Group for $2.8 billion while posting zero trailing revenue and burning $47 million in cash annually. BlackRock's simultaneous 5.9% passive entry and two bullish analyst calls validate the Western supply-chain narrative, but dilutive equity financing subject to shareholder vote and a 128% prior-year run leave shareholders absorbing significant execution risk against a pre-revenue company attempting a cross-border integration.

MANEBriefMay 1 · May 1, 2026

Veradermics Prices $384M Stock Offering at $100 After Hair Loss Drug Hits Phase 2/3 Goals

Veradermics priced an upsized 3.84M-share offering at $100 plus a $300k warrant PIPE after VDPHL01 hit positive Phase 2/3 hair growth endpoints, funding commercialization but adding dilution.

ENPHAnalysisApr 29 · Apr 29, 2026

Enphase Slides As Tax Credit Expiry Hits Q1 Demand

Enphase Energy's Q1 2026 print on April 28 sent shares lower in after-hours trading as the expiry of a federal tax credit gutted U.S. residential solar demand. A simultaneous AI data center pivot offers a long-dated optionality story, but a director's $6 million stock sale six weeks before the print suggests at least one insider didn't want to wait around for it.

ENPHBriefApr 29 · Apr 29, 2026

Enphase Energy Beats EPS But U.S. Solar Demand Cracks After Tax Credit Expires

Enphase Energy beat Q1 2026 EPS estimates but revenue and adjusted earnings declined YoY as U.S. solar demand softened after the federal tax credit lapsed, while the company announced a new AI data center transformer aimed at GPU power density.

ERASAnalysisApr 28 · Apr 28, 2026

Erasca Plunges 40% on Trial Death, Patent Threat

Erasca shares collapsed roughly 40% in after-hours trading after Phase 1 data for ERAS-0015 revealed a treatment-related patient death alongside otherwise strong tumor response rates, while Revolution Medicines added pressure with patent infringement allegations. The stock faces a rare confluence of clinical, legal, and credibility risk that will define its next chapter.

ORKABriefApr 28 · Apr 28, 2026

Oruka Therapeutics Stock Hits Record High on Psoriasis Drug Data, Then Launches $500M Offering

Oruka Therapeutics surged to a record high after Phase IIa data showed 64% skin clearance for its once-yearly psoriasis drug, then launched a $500M public offering that could dilute shareholders.

MANEBriefApr 28 · Apr 28, 2026

Veradermics Surges 50% on Hair Loss Trial Results, Then Sells $213M in Stock

Veradermics surged on positive Phase 2/3 hair loss trial results but simultaneously launched a dilutive $212.9M offering, signaling a long and expensive road to commercialization.

CLFAnalysisApr 26 · Apr 26, 2026

Cleveland-Cliffs Q1: Tariff Tailwinds Meet Cold Reality

Cleveland-Cliffs reported Q1 results showing $4.9B in steel sales offset by an $80M cold-weather hit and persistent negative margins, sending shares down 5%. The stock is caught between tariff-driven deal speculation and a balance sheet that keeps bleeding cash.

HIMSBriefApr 26 · Apr 26, 2026

Hims & Hers Health Gets JPMorgan's Blessing at $35 — But the FDA Holds the Real Vote

JPMorgan initiated Hims & Hers Health at Overweight with a $35 price target, while Eli Lilly expanded its LillyDirect GLP-1 partnership, but FDA compounding enforcement remains the binary risk to the thesis.

HTZAnalysisApr 23 · Apr 23, 2026

Hertz Stock Drops 10% as Short Squeeze Unwinds

Hertz shares fell more than 10% on April 23 as short-squeeze dynamics that fueled a parabolic rally showed signs of exhaustion, compounded by a sector-wide selloff triggered by Barclays' downgrade of Avis Budget. At $6.60, the stock trades 52% above the mean analyst price target of $4.33, while fundamentals show persistent losses, razor-thin margins, and near-zero free cash flow.

RCUSBriefApr 22 · Apr 22, 2026

Arcus Biosciences Stock Rebounds 7.8% After Lung Cancer Trial Fails — Here's the Twist

Arcus Biosciences discontinued its Phase 3 lung cancer trial for futility, but the stock rebounded 7.8% as analysts flagged Merck's belzutifan failure opening a competitive window in renal cell carcinoma.

VMIBriefApr 22 · Apr 22, 2026

Valmont Industries Surges 13% as Utility Infrastructure Demand Lifts Earnings Past Estimates

Valmont Industries beat Q1 2026 estimates on strong utility infrastructure demand and raised the low end of full-year EPS guidance, sending shares up 13%.

NKTRBriefApr 21 · Apr 21, 2026

Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%

Nektar Therapeutics is raising $250 million in a public stock offering timed to an 18.3% rally on positive alopecia trial data, a classic biotech move that funds the pipeline but dilutes existing shareholders.

LEGNBriefApr 21 · Apr 21, 2026

Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal

Eli Lilly struck a ~$7 billion deal tied to Legend Biotech's CARVYKTI cancer therapy, sending LEGN shares up as much as 18% for the stock's best session in three years.

ONDSBriefApr 20 · Apr 20, 2026

Ondas Holdings Lands $118 Million in Defense Contracts, More Than Double Its Annual Revenue

Ondas Holdings secured a $10M initial order from a $50M border demining contract and a separate $68M defense order, combining for more than twice its trailing twelve-month revenue.

KLRABriefApr 18 · Apr 18, 2026

Kailera Therapeutics Raises $625 Million in Biotech's Biggest IPO, Then Pops 63%

Kailera Therapeutics priced one of biotech's largest-ever IPOs at $625 million and saw shares surge roughly 63% on their first day, reflecting intense investor appetite for obesity therapeutics.

BBBriefApr 17 · Apr 17, 2026

BlackBerry Limited Surges 11% as QNX Growth Turns Turnaround Talk Into Real Numbers

BlackBerry shares jumped 11% after QNX posted record growth and management issued above-consensus guidance, crossing the 200-day moving average for the first time in months.

BBAnalysisApr 17 · Apr 17, 2026

BlackBerry Stock Surges 11% After Earnings Beat and Strong QNX Growth

BlackBerry Limited shares rose approximately 11% on April 17, 2026, crossing above the 200-day moving average after the company posted its third consecutive quarterly earnings beat and QNX division growth topped expectations. Insider selling by four executives in early April and a mean analyst price target only 2.6% above the current price suggest limited near-term upside from here.

HIMSAnalysisApr 16 · Apr 16, 2026

Hims & Hers Trades 10% Above BofA's Raised $25 Target as Novo Nordisk Launches Direct Wegovy Sales

Hims & Hers stock has run past both the $24 consensus target and BofA's freshly raised $25 price target on a regulatory signal that the FDA will reassess peptide compounding rules. Novo Nordisk's new direct Wegovy subscription, announced in the same news cycle, targets the price-arbitrage model that anchors the HIMS GLP-1 franchise.

TNGXBriefApr 15 · Apr 15, 2026

Tango Therapeutics Overhauls C-Suite With Three Senior Hires to Push Pancreatic Cancer Drug Toward Approval

Tango Therapeutics appointed Matthew Gall as CFO and hired two additional senior executives to accelerate late-stage development of pancreatic cancer drug vopimetostat, a move backed by a concurrent Leerink price target raise.

TVTXBriefApr 15 · Apr 15, 2026

Travere Therapeutics Surges 33% After FDA Approves the Only Drug for Rare Kidney Disease

Travere Therapeutics stock surged after FILSPARI became the first and only FDA-approved treatment for focal segmental glomerulosclerosis, a rare kidney scarring disease with no competing therapies.

SYREBriefApr 14 · Apr 14, 2026

Spyre Therapeutics Hits 4-Year High on Trial Win, Then Sells $300 Million in Stock

Spyre Therapeutics' SPY001 met all Phase 2 endpoints for ulcerative colitis, prompting analyst upgrades and a 4-year share price high, but the company moved quickly to sell $300 million in new stock.

TLXBriefApr 11 · Apr 11, 2026

Telix Pharmaceuticals Jumps After FDA Accepts Brain Cancer Drug Filing

FDA accepted Telix Pharmaceuticals' NDA filing for its brain cancer imaging agent Pixclara, setting up a binary approval catalyst for the $804mn-revenue radiopharmaceutical company.

IBRXBriefApr 10 · Apr 10, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

ImmunityBio confirmed its pivotal BCG-naive bladder cancer trial has adequate statistical power for a 2026 supplemental filing, but an FDA warning letter over misleading Anktiva promotional claims has triggered a 21% stock drop and class action lawsuits.

BBBriefApr 9 · Apr 9, 2026

BlackBerry Swings to $53 Million Profit as QNX Revenue Hits Record, Stock Jumps 11%

BlackBerry reported Q4 revenue of $156M, beating estimates by 8%, as its QNX automotive software division hit a record quarter and the company posted its first full-year GAAP profit in years.

RLAYBriefApr 8 · Apr 8, 2026

Relay Therapeutics Jumps 16% on New Clinical Data for Its Lead Drug Outside Cancer

Relay Therapeutics surged 16% ahead of its first clinical data presentation for Zovegalisib in vascular anomalies, a new therapeutic area that could expand the drug's market beyond oncology.

ONDSBriefApr 5 · Apr 5, 2026

Ondas Inc. Revenue Jumps 629% but Losses Keep Growing — Here's the Trade-Off

Ondas posted record Q4 revenue with 629% year-over-year growth and raised fiscal 2026 guidance, but widening net losses and two acquisitions raise questions about cash burn and dilution.

IBRXAnalysisApr 3 · Apr 3, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

The FDA issued an enforcement action calling ImmunityBio's promotional claims for ANKTIVA "misleading," directly undermining the commercial adoption narrative behind the stock's $6.7 billion valuation. With 31% annual share dilution and $309 million in cash burn against just $113 million in revenue, existing shareholders face value erosion even if the drug succeeds.

RLAYBriefApr 3 · Apr 3, 2026

Relay Therapeutics Jumps 16% on New Clinical Data for Its Cancer Drug in Rare Disease

Relay Therapeutics gained 16% after announcing initial clinical data on Zovegalisib in vascular anomalies at the ISSVA World Congress, potentially validating the drug's platform value beyond oncology.

KODBriefApr 2 · Apr 2, 2026

Kodiak Sciences Aces Second Phase 3 Trial for Zenkuda in Diabetic Retinopathy

Kodiak Sciences reported positive GLOW2 Phase 3 results showing Zenkuda achieved a 62.5% response rate vs 3.3% for sham in diabetic retinopathy, giving the company two pivotal wins and a clear runway to file for FDA approval.

IBRXBriefApr 2 · Apr 2, 2026

ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month

ImmunityBio confirmed statistical power in its pivotal ANKTIVA bladder cancer trial but faces an offsetting FDA warning that turns the stock into a pure regulatory coin flip.

MLYSAnalysisApr 1 · Apr 1, 2026

Mineralys Therapeutics Just Lost Its Most Important Drug Trial: and Analysts Still Say Buy

The Explore-OSA trial failure eliminates lorundrostat's most differentiated indication expansion, leaving Mineralys to compete head-to-head against AstraZeneca's baxdrostat on a narrower combination-therapy label. The Street's $49 consensus target still prices in broad franchise optionality that the data no longer supports.

PRAXBriefApr 1 · Apr 1, 2026

Praxis Precision Medicines Wins FDA Priority Review for Relutrigine NDA

Praxis Precision Medicines received FDA acceptance and Priority Review designation for its relutrigine NDA in rare pediatric epilepsy, compressing the approval timeline to roughly 6 months and marking a major de-risking event for the clinical-stage biotech.

CNTABriefApr 1 · Apr 1, 2026

Eli Lilly to Buy Centessa Pharmaceuticals for Up to $7.8bn in Neuro Push

Eli Lilly announced a deal to acquire Centessa Pharmaceuticals for up to $7.8bn, paying $6.3bn upfront to secure the biotech's orexin receptor pipeline for sleep-wake disorders.

KODAnalysisMar 27 · Mar 27, 2026

Kodiak Sciences Needs Second Phase 3 Trial Despite "Superiority" Claims

Kodiak Sciences announced positive GLOW2 Phase 3 results for tarcocimab tedromer, but the need for a second confirmatory study suggests regulatory complexity. Multiple Phase 3 trials typically indicate FDA feedback requiring additional evidence or suboptimal initial results.

KODBriefMar 26 · Mar 26, 2026

Kodiak Sciences Posts Positive Phase 3 Diabetic Retinopathy Results

Kodiak Sciences announced positive topline results from its GLOW2 Phase 3 trial showing tarcocimab tedromer demonstrated superiority over sham treatment in diabetic retinopathy.

KODAnalysisMar 26 · Mar 26, 2026

Kodiak Sciences Phase 3 Superiority Creates $400M Partnership Window

Kodiak Sciences' Phase 3 superiority results for tarcocimab tedromer in diabetic retinopathy significantly de-risk regulatory approval. With $42M quarterly cash burn and 12-month runway, the positive data creates enhanced partnership negotiating leverage that consensus 1.9% upside fails to capture.

WVEBriefMar 26 · Mar 26, 2026

Wave Life Sciences Plunges 56% Despite Obesity Drug Data

Wave Life Sciences stock plummeted 56% after reporting interim Phase 1 data for obesity drug WVE-007 that showed visceral fat reduction but failed to meet investor expectations.

ALMAnalysisMar 26 · Mar 26, 2026

Almonty Industries Gets 35% Analyst Target Hike as Tungsten Crisis Deepens

B. Riley raised Almonty Industries' price target 35% from $17 to $23, the largest tungsten sector revision in months. The move suggests material developments around production timelines or strategic partnerships that the market hasn't priced in.

CORTBriefMar 26 · Mar 26, 2026

Corcept Therapeutics Gets FDA Approval for Ovarian Cancer Drug

FDA approved Corcept Therapeutics' Lifyorli combination therapy for platinum-resistant ovarian cancer, marking the company's expansion into oncology.

SRPTBriefMar 26 · Mar 26, 2026

Sarepta Therapeutics Surges 35% on Positive siRNA Trial Data

Sarepta Therapeutics surged 35% after releasing positive early clinical data from siRNA trials targeting neuromuscular diseases FSHD1 and DM1, coupled with a Morgan Stanley price target increase.

CORTAnalysisMar 25 · Mar 25, 2026

Corcept Insider Drops $3.3M Just Before FDA Win Signals Hidden Value

A Corcept insider purchased $3.3 million in shares just before the company's FDA approval for Lifyorli, suggesting management confidence in broader platform value beyond the single approved indication. The timing and magnitude indicate the market is undervaluing Corcept's glucocorticoid receptor antagonist platform potential.

HCCAnalysisMar 25 · Mar 25, 2026

Warrior Met Coal Earnings Silence Exposes 7-Month Communication Blackout

Warrior Met Coal has maintained radio silence on earnings and investor communications for seven months, contradicting standard public company disclosure practices. The information vacuum suggests management is either managing severe operational challenges or quietly repositioning the business during the energy transition.